SEER is an authoratitive source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Code grade specified by pathologist. If no grade specified, code 9
Chronic myelocytic leukemia, NOS
Chronic myelogenous leukemia, BCR-ABL1 status unknown
Chronic myelogenous leukemia, NOS
Chronic myeloid leukemia, BCR-ABL1 status unknown, Accelerated phase (AP)
Chronic myeloid leukemia, BCR-ABL1 status unknown, Blast phase (BP)
Chronic myeloid leukemia, BCR-ABL1 status unknown, Chronic phase (CP)
CML, BCR-ABL1 status unknown, Accelerated phase (AP)
CML, BCR-ABL1 status unknown, Blastic phase (BP)
CML, BCR-ABL1 status unknown, Chronic phase (BP)
No delineation of translocation, BCR-ABL1, or Phil chromosome noted to qualify for ICD-O-3 9863.
Specific term as defined by WHO, codes as 9875/3 and indicates the process has Ph+, BCR-ABL1 fusion and/or t(9;22)(q34;q11) demonstrated, as defined by ICD-O-3 for 9875 as well. Presumably myelogenous leukemia without genetic studies done would be coded to 9863.
Chronic myeloid leukemia, NOS is a generic disease description. DCO cases or path report only cases may stay in this classification. In most cases, NOS histology is only the provisional diagnosis; the physician will run further diagnostic procedures and look for various clinical presentations to identify a more specific disease. Further review of the medical record should be done to look for the tests listed as definitive diagnosis. The more specific chronic myeloid leukemias are: Chronic myelogenous leukemia, BCR-ABL1 positive; Atypical chronic myeloid leukemia, BCR-ABL1 negative; Chronic myelomonocytic leukemia; and Juvenile myelomonocytic leukemia. If the characteristics of a specific subtype of chronic myeloid leukemia develop later in the course of the disease, change the histology code to the more specific diagnosis.
Chronic phase: Tyrosine kinase inhibitor. High-dose chemotherapy with donor stem cell transplant; BRM (interferon). OR Chemotherapy; splenectomy; clinical trial of lower-dose chemotherapy with donor stem cell transplant.
Accelerated phase: Donor stem cell transplant;; tyrosine kinase inhibitor; BRM, (interferon (with or without chemotherapy). Chemotherapy may be a single or multi-drug regimen.